Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 501–600 of 1,008
Wang, H., Pan, J., Zhang, M., & Tan, Z. F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599048 · Cited by 44
Chemical imaging delineates Aβ plaque polymorphism across the Alzheimer’s disease spectrum
Koutarapu, S., Ge, J., Dulewicz, M., Srikrishna, M., Szadziewska, A., Wood, J. I., Blennow, K., Zetterberg, H., Michno, W., Ryan, N. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59085-7 · Cited by 32
Kelliny, S., Zhou, X., & Bobrovskaya, L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70046 · Cited by 30
Alves, I. L., Heeman, F., Collij, L. E., Salvadó, G., Tolboom, N., Vilor‐Tejedor, N., Markiewicz, P. J., Yaqub, M. M., Cash, D. M., Mormino, E. C., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00819-2 · Cited by 24
“It is important to note that all results in this work relate to a fixed effect (20%) of reducing the accumulation rates in amyloid PET scans, which may seem disconnected from the level of amyloid removal observed in recent anti-amyloid immunotherapies [7, 59].”
ResultDomingo, G., Benussi, L., Saraceno, C., Bertuzzi, M., Nicsanu, R., Longobardi, A., Bellini, S., Cagnotto, A., Salmona, M., Binetti, G. G., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708119 · Cited by 22
Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 25
Glymour, M. M., Weuve, J., Dufouil, C., & Mayeda, E. R. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac063 · Cited by 21
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease
Lozupone, M., Berardino, G., Mollica, A., Sardone, R., Dibello, V., Zupo, R., Lampignano, L., Castellana, F., Bortone, I., Stallone, R., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2095261 · Cited by 23
“[31] and donanemab [32] showed encouraging results, with preliminary data suggesting an effect of treatment on tau protein biomarkers, which could be a surrogate AD marker [33].”
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
“amyloid beta and abnormal deposition of tau protein, first against the pathological characteristics of drugs.(213,214) We summarize the Aβ antibodies that have entered clinical trials recently (Table 5).”
BackgroundPhytochemicals targeting lncRNAs: A novel direction for neuroprotection in neurological disorders
Zhao, H., Wang, L., Zhang, L., & Zhao, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114692 · Cited by 22
Evans, C. D., Sparks, J., Andersen, S. W., Brooks, D. A., Hauck, P. M., Mintun, M. A., & Sims, J. R. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13128 · Cited by 26
“14,19,21,23 In this report, the ADAS-Cog 13 data were used from the donanemab, aducanumab, and solanezumab trials, and the ADAS-Cog 14 datawereusedfromthelecanemabtrial.”
MethodSelf-citationDreves, M. A. E., van Harten, A. C., Visser, L. N. C., Rhodius‐Meester, H. F. M., Köhler, S., Kooistra, M., Papma, J. M., Honey, M. I. J., Blom, M., Smets, E. M. A., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12401 · Cited by 27
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 24
Tolar, M., Hey, J. A., Power, A., & Abushakra, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052727 · Cited by 23
“These anti-amyloid antibodies have also shown significant clinical efficacy in Phase 2 and 3 trials in early AD subjects [3,4,27,28], providing strong support for the primary role of oligomers in the pathogenesis of AD and for the validity of oligomers as a therapeutic target [13].”
BackgroundMethodDifferential interaction with TREM2 modulates microglial uptake of modified Aβ species
Joshi, P., Riffel, F., Satoh, K., Enomoto, M., Qamar, S., Scheiblich, H., Villacampa, N., Kumar, S., Theil, S., Parhizkar, S., et al. (2021) · Glia · doi:10.1002/glia.24077 · Cited by 22
Emerging role of Metformin in Alzheimer’s disease: A translational view
Ríos, J. A., Bórquez, J. C., Godoy, J. A., Zolezzi, J. M., Furrianca, M. C., & Inestrosa, N. C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102439 · Cited by 24
Sarkar, S., Bhui, U., Kumar, B., Ashique, S., Kumar, P., Sharma, H., Bhowmick, M., Pal, R., & Kumar, T. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822329981241007105405 · Cited by 31
Hsu, C., Hsu, T., Kao, Y., Lin, Y., Thompson, T., Carvalho, A. F., Stubbs, B., Tseng, P., Yang, F., Tsai, C., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100195 · Cited by 28
“In-deed, RCTs have shown that mABs can significantly reduce amyloid-𝛽 burden, as measured by positron emission tomography (PET) scans [ 11– 13 ].”
InfluentialScherlek, A. A., Kozberg, M. G., Nicoll, J. A. R., Perosa, V., Freeze, W. M., van der Weerd, L., Bacskai, B. J., Greenberg, S. M., Frosch, M. P., Boche, D., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac021 · Cited by 21
“6 Both subtypes were initially observed in active immunization trials and were defined as subacute meningoencephalitis,(9) and have now also been reported in multiple passive immunotherapy trials with rates of up to 40% in the Phase 1b and Phase 3 aducanumab(11,12) and Phase 2 donanemab trials.(28) ARIA is usually asy…”
Punyakoti, P., Behl, T., Sehgal, A., Yadav, S., Sachdeva, M., Anwer, M. K., Vargas-De-La-Cruz, C. B., Venkatachalam, T., Naqvi, M., Verma, R., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110539 · Cited by 21
Functions of glutaminyl cyclase and its isoform in diseases
Liu, Y., Shi, Y., & Wang, P. (2023) · Visualized Cancer Medicine · doi:10.1051/vcm/2022008 · Cited by 21
Drug trial for Alzheimer’s disease is a game changer
Reiman, E. M. (2023) · Nature · doi:10.1038/d41586-023-00393-7 · Cited by 20
Sauty, B., & Durrleman, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1161527 · Cited by 26
“On the other hand, trials for Donanemab (16) and Aducanumab (17) display similar enrollment demographics, but do not report results by sex.”
BackgroundDonanemab exposure and efficacy relationship using modeling in Alzheimer's disease
Gueorguieva, I., Willis, B. A., Chua, L., Chow, K. H., Ernest, C. S., Wang, J., Shcherbinin, S., Sims, J. R., & Chigutsa, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12404 · Cited by 27
Self-citationParrado‐Fernández, C., Juric, S., Backlund, M., Dahlström, M., Madjid, N., Lidell, V., Rasti, A., Sandin, J., Nordvall, G., & Forsell, P. K. A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311159 · Cited by 21
“The results from later-stage clinical trials with the two approved anti-amyloid monoclonal antibodies, aducanumab and lecanemab [30], as well as the more recently described and not yet approved donanemab [31], have only demonstrated a 35% reduction in deterioration of the integrated Alzheimer’s disease rating scale (i…”
BackgroundProfiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
Bucci, M., Blūma, M., Savitcheva, I., Ashton, N. J., Chiotis, K., Matton, A., Kivipelto, M., Molfetta, G. D., Blennow, K., Zetterberg, H., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02558-4 · Cited by 23
“6 years [26]; in two clinical trial studies lasted around 75 weeks, the placebo arms did not result in significant changes in Aβ PET quantification [27, 28].”
BackgroundImmunotherapy: An emerging treatment option for neurodegenerative diseases
Mukherjee, A., Biswas, S., & Roy, I. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103974 · Cited by 23
Tariot, P. N., Riviere, M., Salloway, S., Burns, J. M., Snædal, J., Borowsky, B., Lopez, C. L., Liu, F., Rouzade‐Dominguez, M., Cazorla, P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14237 · Cited by 22
Self-citationAducanumab and the “post-amyloid” era of Alzheimer research?
Musiek, E. S., & Bennett, D. A. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.007 · Cited by 22
Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease
Olloquequi, J., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Carrasco, M., Espinosa-Jiménez, T., Beas‐Zárate, C., Gudiño‐Cabrera, G., Ureña‐Guerrero, M. E., Verdaguer, E., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705146 · Cited by 27
“In turn, donanemab, which targets A β plaques, re-ported both a decrease in A β aggregates and a reduction in the rate of cognitive and functional decline in a phase II study [71]; while a larger phase III trial is underway (NCT # 04437511).”
BackgroundHoldridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13031 · Cited by 19
Self-citationFeldman, H., for the ADCS VIVA-MIND Study Group, Messer, K. S., Qiu, Y., Sabbagh, M., Galasko, D., Turner, R. S., López, O. L., Smith, A., Durant, J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231126 · Cited by 23
Immune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy
Balkhi, S., Spirito, A. D., Poggi, A. D., & Mortara, L. (2025) · Cells · doi:10.3390/cells14040264 · Cited by 24
“However, donanemab was also linked to a higher incidence of ARIA-E compared to placebo (26.7% vs. 0.8%), under-scoring the need for larger, longer trials to thoroughly evaluate its safety and efficacy [135].”
InfluentialChen, S., Ou, R., Wei, Q., Li, C., Wei, S., Zhao, B., Yang, H. J., Fu, J., Ma, Y., Liu, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70750 · Cited by 27
“32,33 Notably, in our study, the decline in p-tau181 preceded that of p-tau217 and showed a stronger correlation with cognitive improvement.”
Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease
Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025) · Brain Sciences · doi:10.3390/brainsci15101101 · Cited by 22
“Supported by these results, donanemab (Kisunla) received FDA approval in July 2024 for early symptomatic AD [133,134], following positive results from the Phase 3 TRAILBLAZER-ALZ 2 trial [17].”
Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 24
“Nonetheless, quantitative CSF α -synuclein assays may hold value for monitoring responses to DMTs in PD (Alfaidi et al., 2024).”
InfluentialMichno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 19
Zhu, H., Mehta, M., Huang, S. M., & Wang, Y. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2536 · Cited by 20
“aducanumab (baseline Centiloid ~ 80).(8)Aβ, beta- amyloid; AlZ, Study TRAILBLAZER- ALZ; Car, Study in APOE”
BackgroundMesial temporal tau in amyloid-β-negative cognitively normal older persons
Krishnadas, N., Doré, V., Groot, C., Lamb, F., Bourgeat, P., Burnham, S. C., Huang, K., Goh, A., Masters, C. L., Villemagne, V. L., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00993-x · Cited by 23
“There is a shift in AD clinical trials toward the pre-clinical stages of disease, with trials aiming to screen healthy older individuals with Aβ and tau biomarkers [18, 19].”
BackgroundMini review: Prospective therapeutic targets of Alzheimer's disease
Mangal, R., & Ding, Y. (2022) · Brain Circulation · doi:10.4103/bc.bc_20_21 · Cited by 19
“It provides hope for the elimination of amyloid plaques.[5]”
BackgroundArendash, G. W., Abulaban, H., Steen, S., Andel, R., Wang, Y., Bai, Y., Baranowski, R., McGarity, J., Scritsmier, L., Lin, X., et al. (2022) · Medicines · doi:10.3390/medicines9080042 · Cited by 21
“Although such cognitive composite scores have been used occasionally to track “preclinical” AD cognitive decline [46–48], they are rarely used in AD intervention trials [49,50].”
A Step Forward in the Fight Against Dementia—Are We There Yet?
Wolk, D. A., Rabinovici, G. D., & Dickerson, B. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0123 · Cited by 17
Advances in the treatment and management of frontotemporal dementia
Benussi, A., & Borroni, B. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2228491 · Cited by 19
White, J. P., Schembri, A. J., Prenn-Gologranc, C., Ondrus, M., Katina, S., Novák, P., Lim, Y. Y., Edgar, C. J., & Maruff, P. T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230352 · Cited by 21
Current status of PET tracers for the early diagnosis of Alzheimer's disease
Li, Y., Liu, T., Zeng, Q., & Cui, M. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117546 · Cited by 20
Zeng, B., Tang, C., Wang, J., Yang, Q., Ren, Q., & Liu, X. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240161 · Cited by 25
Penny, L. K., Lofthouse, R. A., Arastoo, M., Porter, A., Palliyil, S., Harrington, C. R., & Wischik, C. M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00417-w · Cited by 21
“It is also of note that tau PET still has great utility in amyloid-targeting trials for participant selection and as a downstream marker of AD pathology [80, 81].”
BackgroundNew insights into innate immunity in Alzheimer’s disease: From APOE protective variants to therapies
Chen, Y., & Holtzman, D. M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.001 · Cited by 19
Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran
Grossmann, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094805 · Cited by 20
“These and other anti-Aβ antibodies, such as gantenerumab, BAN2401, are currently under clinical investigation [3,32,33].”
BackgroundHoffmann, T., Rahfeld, J., Schenk, M., Ponath, F., Makioka, K., Hutter‐Paier, B., Lues, I., Lemere, C. A., & Schilling, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111791 · Cited by 21
“Among these antibody molecules, Donanemab recently showed significant removal of amyloid load and cognitive stabilization in a Phase 2 clinical trial [6,7].”
BackgroundStaerz, S. D., Jones, C. L., & Tepe, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02158 · Cited by 21
Logroscino, G., Urso, D., Gnoni, V., Giugno, A., Vilella, D., Castri, A. D., Barone, R. M. E., Nigro, S. L., Zecca, C., Blasi, R. D., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16534 · Cited by 23
“However, the number of such subjects is likely to be very limited; in the future, having a bio - marker of tau downstream pathology is an additional piece of informa - tion that will be used as in the most recent donanemab trial [ 1].”
Hu, H., Wan, S., Hu, Y., Wang, Q., Li, H., & Zhang, N. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2445194 · Cited by 21
“Clinical trials of the FDA-approved drugs lecanemab and donanemab have revealed that APOE ɛ 4 homozygotes receiving passive Aβ immunotherapy presented a much higher incidence of ARIA-edema/effusion and ARIA-hemosiderosis/microhemorrhages than APOE ɛ 4 heterozygotes and noncarriers [82,83].”
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 20
Fang, R., Jin, L., Lu, H., Xie, Q., Yang, X., & Kueckelhaus, M. (2025) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000011535 · Cited by 22
Recent Advances in Antibody Therapy for Alzheimer’s Disease: Focus on Bispecific Antibodies
Yang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136271 · Cited by 21
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 26
“Indeed, the efficacy of donanemab in clinical trials was inversely associated with PET-detectable tau load among individuals with a moderate tau burden 51 , shedding light on the role of tau PET in the stratification of candidates for anti-Aβ treatments.”
InfluentialMore Alzheimer’s drugs head for FDA review: what scientists are watching
Mullard, A. (2021) · Nature · doi:10.1038/d41586-021-03410-9 · Cited by 20
Disease progression model using the integrated Alzheimer's Disease Rating Scale
Gueorguieva, I., Chua, L., Willis, B. A., Sims, J. R., & Wessels, A. M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12876 · Cited by 19
Self-citationClinical trials for cognition in Parkinson's disease: Where are we and how can we do better?
Bayram, E., Batzu, L., Tilley, B. S., Gandhi, R., Jagota, P., Biundo, R., Garon, M., Prasertpan, T., Lazcano‐Ocampo, C., Chaudhuri, К. R., et al. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105385 · Cited by 24
“To detect any effects on long-term cognition, trials will need to be designed with longer duration, ideally over 18 months, as is the case for trials of disease modifying treatments in dementia [49–51].”
Targeting Progranulin as an Immuno-Neurology Therapeutic Approach
Boylan, M. A., Pincetic, A., Romano, G. J., Tatton, N. A., Kenkare-Mitra, S., & Rosenthal, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115946 · Cited by 19
A glance through the effects of CD4 + T cells, CD8 + T cells, and cytokines on Alzheimer's disease
Afsar, A., Chen, M., Xuan, Z., & Li, Z. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.058 · Cited by 22
“Numerous studies have demonstrated that antibodies against A 𝛽 can robustly clear amyloid plaques and slow cognitive decline in AD [39–42].”
BackgroundAlzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
Gobom, J., Brinkmalm, A., Brinkmalm, G., Blennow, K., & Zetterberg, H. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100721 · Cited by 23
“There are six splicing variants of tau that differ in the number of repeats in the microtubule-binding domain (3R or 4R) (40) as well as by the presence or the absence of N-terminal inserts (4).”
BackgroundKelley, A. S., Addie, S., Carrington‐Lawrence, S., Ferrucci, L., Jones, P., Hadley, E., Haim, T., Harper, J., Kahana, S. Y., Kelley, M. S., et al. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18837 · Cited by 22
“11”
Francisco, T. N., Malafaia, D., Melo, L., Silva, A. M. S., & Albuquerque, H. M. T. (2024) · ACS Omega · doi:10.1021/acsomega.3c10417 · Cited by 18
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
Yoon, C. H., Groff, C., & Criss, O. (2024) · INNOVATIONS in pharmacy · doi:10.24926/iip.v15i1.5787 · Cited by 21
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
“Donanemab 141 : As an antibody against deposited A β , it could improve composite scores for cognition and activities of daily living in patients with early AD, but amyloid ‐ associated cerebral edema or hydrocephalus (mostly asymptomatic) also occurred.”
BackgroundGarcía‐Gutiérrez, F., Hernández-Lorenzo, L., Cabrera‐Martín, M. N., Matías‐Guiu, J. A., & Ayala, J. L. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120695 · Cited by 24
Neurodegenerative diseases early detection and monitoring system for point-of-care applications
Thakur, R. R., Saini, A. K., Taliyan, R., & Chaturvedi, N. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.112280 · Cited by 22
Cheon, J., Kwon, S.-Y., & Kim, M. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14432 · Cited by 22
“…focused on the potentiating effects of neurotransmitters within synapses using acetylcholinesterase inhibitors (i.e., donepezil, rivastigmine, and galan-tamine), N -methyl-D-aspartate (NMDA) receptor antagonist (i.e., memantine), 7 and anti-A β immuno-therapies (i.e., lecanemab 8 and donanemab 9 ).”
Garibotto, V., Albert, N. L., Barthel, H., van Berckel, B. N. M., Boellaard, R., Brendel, M., Cecchin, D., Ekmekçioğlu, Ö., van de Giessen, E., Guedj, É., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05485-y · Cited by 18
“, bapineuzumab [17], solanezumab [18], or crenezumab [19], some more recently developed molecules have shown larger effects on amyloid load including aducanumab [20], donanemab [21], gantenerumab [22], and lecanemab [23].”
BackgroundRole of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease
Argueta, N., Notari, E., & Szigeti, K. (2022) · CNS Drugs · doi:10.1007/s40263-022-00915-3 · Cited by 19
“ARIA-E was also APOE4 dependent in a phase IIB study of donanemab, with up to 44% of APOE4 homozygous participants demonstrating ARIA-H on magnetic resonance imaging [50].”
BackgroundMorito, T., Qi, M., Kamano, N., Sasaguri, H., Bez, S., Foiani, M., Duff, K., Benner, S., Endo, T., Hama, H., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101024 · Cited by 18
Ribba, B., Simuni, T., MAREK, K. L., Siderowf, A. D., Diack, C., Pierrillas, P. B., Monnet, A., Ricci, B., Nikolcheva, T., & Pagano, G. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230446 · Cited by 17
Joynes, C. M., Bilgel, M., An, Y., Moghekar, A., Ashton, N. J., Kac, P. R., Karikari, T. K., Blennow, K., Zetterberg, H., Thambisetty, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14405 · Cited by 19
Alzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 21
“Afterward, in phase II (NCT01767311) for 18 months, 856 patients with early AD treated with antibodies (lecanemab and donanemab) together demonstrated the reduction of amyloid burden and delaying of disease development linked with an Aβ-clearing treatment [357,358].”
The Role of Amyloid- and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y., Joie, R. L., & Rabinovici, G. D. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 26
“Recently, lecanemab and donanemab ( 7 – 9 ), 2 monoclonal antibodies targeting A b , were fi rst approved by the Food and Drug Administration (FDA), and now drugs in this class have been approved by the European Medicines Agency and other regulatory agencies across the world.”
Bayer, T. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710579 · Cited by 20
Developments in understanding early onset Alzheimer's disease
Griffin, P. Y., Apostolova, L. G., Dickerson, B. C., Rabinovici, G. D., Salloway, S., Brandt, K., Masdeu, J. C., Hammers, D. B., Raghuram, S., Hall, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13353 · Cited by 23
Self-citationSexton, C. E., Bitan, G., Bowles, K. R., Bryś, M., Buée, L., Maina, M. B., Clelland, C. D., Cohen, A. D., Crary, J. F., Dage, J. L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13533 · Cited by 16
“116 In a phase 2 trial of donanemab in patients with early symptomatic AD, screening procedures included PET with injection of 18F-flortaucipir, MRI, and PET with injection of 18F-florbetapir.”
BackgroundGinkgo biloba and Its Chemical Components in the Management of Alzheimer’s Disease
Peng, Y., Chen, Q., Xue, Y.-H., Jin, H., Liu, S., Du, M., & Yao, S. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500277 · Cited by 23
Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024) · Brain Sciences · doi:10.3390/brainsci14100990 · Cited by 23
“Additionally, the CDR-SB score showed that Donanemab slowed cognitive deterioration by 36% after 18 months [35,36].”
MethodSanotra, M. R., Huang, W., Silver, S. D., Lin, C., Chang, T.-C., Nguyen, D. P. Q., Lee, C., Kao, S., Shieh, J. C.-C., & Lin, Y. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.12.005 · Cited by 19
Aldea, R., Grimm, H. P., Gieschke, R., Hofmann, C., Lott, D., Bullain, S., Delmar, P., Klein, G., Lyons, M., Piazza, F., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12306 · Cited by 16
Alzheimer’s drugs: Does reducing amyloid work?
Thambisetty, M., Howard, R. J., Glymour, M. M., & Schneider, L. S. (2021) · Science · doi:10.1126/science.abl8366 · Cited by 16
Chundu, U. C., Thiriveedhi, S. R., Bhatti, C., Mupparaju, J. S., Otinashvili, N., & Gelishvili, E. (2025) · Cureus · doi:10.7759/cureus.85377 · Cited by 17
A review of neuroimaging-based data-driven approach for Alzheimer’s disease heterogeneity analysis
Liu, L., Sun, S., Kang, W., Wu, S., & Lin, L. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0033 · Cited by 16
“These drugs have been developed with the aim of promoting the clearance of A β aggregates in the brain (Mintun et al. 2021; van Dyck et al. 2023).”
BackgroundDo microglia metabolize fructose in Alzheimer’s disease?
Sturno, A. M., Hassell, J. E., Lanaspa, M. A., & Bruce, K. D. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03401-x · Cited by 21
Advancements in the treatment of Alzheimer's disease: a comprehensive review
Rajanna, S., Gundale, P. P., & Mahadevaiah, A. D. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0204 · Cited by 22
“From a mechanism of action (MoA) perspective, all these therapies target high molecular weight fibrillar A β aggregates, resulting in significant A β reduction observed on amyloid PET scans and associated with amyloid-related imaging abnormalities (ARIA) 11 .”
Influential“Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting
Vigneswaran, S., Vijverberg, E. G. B., Barkhof, F., van de Giessen, E., Lemstra, A. W., Pijnenburg, Y. A. L., Teunissen, C. E., van der Flier, W. M., & van Harten, A. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70375 · Cited by 28
Kapasi, A., James, B. D., Yu, L., Sood, A., Arvanitakis, Z., Bennett, D. A., Boyle, P. A., & Schneider, J. A. (2025) · Neurology · doi:10.1212/wnl.0000000000214004 · Cited by 22
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 18
“Although these agents may slow cognitive decline or improve symptoms, their overall effect on disease progression remains modest (Arvanitakis et al. 2019; Mintun et al. 2021).”
Reduced ULK1 links impaired autophagy and mitophagy to Alzheimer’s disease pathology
Pan, J., Wang, P.-J., Zhang, J., Knapskog, A., Watne, L. O., Wang, H.-L., Lagartos-Donate, M. J., Lautrup, S., Mao, L.-P., Wang, Q., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01108-z · Cited by 22
“Looking ahead, recent advances with anti-Aβ antibodies lecanemab and donanemab show promising clinical efficacy, reducing memory decline by 25–35%, despite some associated adverse effects 70,71 .”
Donanemab removes Alzheimer's plaques: what is special about its target?
Alawode, D. O. T., Heslegrave, A., Fox, N. C., & Zetterberg, H. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00144-6 · Cited by 18
Siddique, Y. H., Naz, F., Rahul, & Varshney, H. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100120 · Cited by 20
Boustani, M. A., Doty, E. G., Garrison, L. P., Smolen, L. J., Belger, M. A., Klein, T. M., Murphy, D. R., Burge, R. T., Wall, J. K., & Johnston, J. A. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.008 · Cited by 17
Comparing ARIA‐E severity scales and effects of treatment management thresholds
Klein, G., Scelsi, M. A., Barakos, J. A., Fiebach, J. B., Bracoud, L., Suhy, J., Delmar, P., Lyons, M., Wojtowicz, J., Bullain, S., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12376 · Cited by 19
Ali, N., Liu, J. H., Tian, H., Pan, W., Tang, Y., Zhong, Q., Gao, Y., Xiao, M., Wu, H., Sun, C., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.992873 · Cited by 18
“org paradigm are well studied in MCI patients, and most studies have reported changes in gait speed under those conditions (Mintun et al., 2021), (Montero-Odasso et al.”
BackgroundWei, N., Liu, H., Ye, W., Xu, S., Lu, C., Dai, A., Hou, T., Zeng, X., Wu, J., & Chen, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14228 · Cited by 18
Ahuja, M., Siddhpuria, S., Karimi, A., Lewis, K., Wong, E. K. C., Lee, J., Reppas‐Rindlisbacher, C. E., Sood, E., Gabor, C., & Patterson, C. (2023) · Age and Ageing · doi:10.1093/ageing/afad205 · Cited by 18
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.